Compare Stocks → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:APHBNASDAQ:CRMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$4.18+2.0%$0.00$0.15▼$1.37$139.90MN/A842,200 shs35,815 shsCRMDCorMedix$4.24+1.9%$3.46$2.57▼$6.09$232.40M1.85539,197 shs339,668 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+1.92%+8.72%+20.11%+12.77%+15.85%Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACRMDCorMedix1.3062 of 5 stars3.50.00.00.02.41.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi BiosciencesN/AN/AN/AN/ACRMDCorMedix3.00Buy$13.00206.60% UpsideCurrent Analyst RatingsLatest CRMD, ARIX, and APHB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.001/31/2024CRMDCorMedixTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/ACRMDCorMedix$60K3,873.38N/AN/A$1.28 per share3.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/ACRMDCorMedix-$46.34M-$0.92N/AN/AN/AN/A-72.31%-63.97%5/20/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/ACRMDCorMedixN/A6.976.78OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/ACRMDCorMedix34.18%Insider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/ACRMDCorMedix3.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableCRMDCorMedix8254.81 million52.84 millionOptionableCRMD, ARIX, and APHB HeadlinesSourceHeadlineCorMedix Inc. to Present at the Needham Annual Healthcare Conferencefinance.yahoo.com - March 27 at 9:34 AMCRMD Apr 2024 6.000 putfinance.yahoo.com - March 16 at 9:19 AMCRMD Apr 2024 3.000 putfinance.yahoo.com - March 16 at 8:46 AMCRMD Apr 2024 3.000 callfinance.yahoo.com - March 16 at 8:16 AMCorMedix Inc. (NASDAQ:CRMD) CEO Joseph Todisco Purchases 13,561 Sharesinsidertrades.com - March 15 at 11:42 AMCorMedix Inc. (NASDAQ:CRMD) CEO Buys $50,718.14 in Stockmarketbeat.com - March 14 at 10:27 AMTruist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)markets.businessinsider.com - March 13 at 8:41 PMAnalysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)markets.businessinsider.com - March 13 at 1:26 PMCorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 13 at 10:40 AMAyr Wellness reports mixed Q4 results; initiates Q1 FY24 outlookseekingalpha.com - March 13 at 8:25 AMBuy Rating on Cormedix Amidst DefenCath Launch and Strong Financial Positioningmarkets.businessinsider.com - March 12 at 10:47 PMCorMedix Shares Move Lower After 4Q Updatemarketwatch.com - March 12 at 5:47 PMAnalysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), PROCEPT BioRobotics (PRCT)markets.businessinsider.com - March 12 at 5:47 PMCorMedix (CRMD) Q4 2023 Earnings Call Transcriptmsn.com - March 12 at 5:47 PMCormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCathfinance.yahoo.com - March 12 at 9:23 AMCorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 12 at 8:22 AMCorMedix: Q4 Earnings Snapshotsfgate.com - March 12 at 8:22 AMCorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 12 at 7:30 AM6CRMD : Cormedix Earnings Previewbenzinga.com - March 11 at 2:55 PMCorMedix (CRMD) Scheduled to Post Earnings on Tuesdaymarketbeat.com - March 7 at 1:08 PMCorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024globenewswire.com - March 6 at 8:30 AMCorMedix (NASDAQ:CRMD) Stock Price Down 3.8%marketbeat.com - March 5 at 5:27 AMCormedix Stock (NASDAQ:CRMD), Short Interest Reportbenzinga.com - February 22 at 10:23 AMCorMedix: Other Events, Financial Statements And Exhibitscbonds.com - February 1 at 8:29 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmpliphi BiosciencesNYSEAMERICAN:APHBAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.CorMedixNASDAQ:CRMDCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.